Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company that is dedicated to developing innovative antiviral therapies for debilitating chronic diseases, specifically focusing on fibromyalgia. The company's lead development candidate, IMC-1, is a proprietary combination of famciclovir and celecoxib designed to suppress herpes virus replication and reduce the symptoms associated with virally promoted diseases. IMC-1 has shown promising results in a Phase 2a clinical trial, demonstrating significant reductions in pain, fatigue, anxiety, and depressive symptoms in fibromyalgia patients.

Virios Therapeutics is also exploring the potential use of IMC-2, a combination of valacyclovir and celecoxib, for managing the symptoms of Long-Covid. The company is dedicated to advancing the understanding and treatment of chronic diseases and aims to provide a new treatment paradigm targeting viral-mediated conditions. Visit their website for more information and to get in touch with the team